Finally, ABCC1/MRP1 was found as an effective transporter of imatinib from chronic myeloid leukemia (CML) cells [63], whereas sorafenib was proposed as a substrate for ABCC2/MRP2 [64], therefore causing sorafenib resistance of renal carcinoma cell lines in vitro. This evidence concerns the gene ABCC1 and renal carcinoma.